To reduce the matrix stiffness, targeting the LOXL2-induced crosslinking through anti-LOXL2 antibody AB0023 has been demonstrated effective in reliving liver fibrosis in animal models (Ikenaga et al., 2017). This evidence concerns the gene LOXL2 and Hepatic fibrosis.